INVESTOR ALERT: Berger Montague Advises Elanco Animal Health (NYSE: ELAN) Investors to Inquire About a Securities Fraud Class Action by December 6, 2024

Core Viewpoint - A lawsuit has been filed against Elanco Animal Health on behalf of investors who purchased its securities during the specified class period, indicating potential legal challenges for the company [1][3]. Company Overview - Elanco Animal Health develops products for both pets and farm animals, including Zenrelia, an oral Janus kinase inhibitor for canine dermatology, and Credelio Quattro, a parasiticide for dogs [3]. FDA Approval Timeline - In November 2023, Elanco set a timeline for U.S. FDA approval of Zenrelia and Credelio Quattro in the first half of 2024 [4]. - By May 2024, Elanco updated its timeline, expecting Zenrelia's approval and commercial launch in Q3 2024, and Credelio Quattro's approval in Q4 2024 [4]. - On June 27, 2024, Elanco indicated that Zenrelia would likely include a boxed safety warning, which could slow product adoption by approximately 25% and delay its approval to Q3 2024, with a potential commercial launch in Q4 2024 [5]. Stock Price Impact - Following the announcement regarding the FDA approval timelines and safety warnings, Elanco's stock price fell by $3.69 per share, or 20$14.28 per share on June 27, 2024 [6].